Form D · Biotechnology
Firefly Bio, Inc.
South San Francisco, CA · CIK 0002006498
Offering snapshot reported Mar 26, 2024 · SEC filing
- Reported sold
- $40M Offering amount: $72M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 18, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 26, 2024 | Initial | $39,999,997 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-508629
Source: Form D, filed Mar 26, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Pankaj Bhargava | Director |
| Peter Colabuono | Director |
| Jerel Davis | Director |
| John Flygare | Executive |
| Todd Foley | Director |
| Bernhard Geierstanger | Executive |
| Scott Hirsch | Director, Executive |
| Alexander Mayweg | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2 Tower Place Unit 14 A
South San Francisco, CA, 94080
South San Francisco, CA, 94080